tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

NKGen Biotech Partners with HekaBio for SNK01 in Japan

Story Highlights
  • NKGen Biotech partners with HekaBio to develop NK cell therapy in Japan.
  • The collaboration targets neurodegenerative diseases, leveraging Japan’s expedited regulatory paths.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
NKGen Biotech Partners with HekaBio for SNK01 in Japan

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

NKGen Biotech ( (NKGN) ) has issued an update.

On July 14, 2025, NKGen Biotech entered into a strategic collaboration agreement with HekaBio K.K. to develop, manufacture, and commercialize NKGen’s SNK01 autologous NK cell therapy in Japan and other agreed territories. HekaBio will lead regulatory activities and clinical trials in Japan, leveraging the country’s expedited regulatory environment for cell therapies. The agreement includes profit-sharing terms and a buy-out option for NKGen. This partnership aims to address significant health challenges in Japan’s aging population, particularly neurodegenerative diseases like Alzheimer’s and Parkinson’s.

More about NKGen Biotech

NKGen Biotech is a clinical-stage biotechnology company based in Santa Ana, California, focusing on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. The company is working on troculeucel, a novel NK cell therapy for neurodegenerative disorders and various cancers.

Average Trading Volume: 177,233

Technical Sentiment Signal: Sell

Current Market Cap: $12.59M

For an in-depth examination of NKGN stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1